Elicera Therapeutics Management
Management criteria checks 2/4
Elicera Therapeutics' CEO is Jamal El-Mosleh, appointed in Jan 2020, has a tenure of 5.08 years. directly owns 8.39% of the company’s shares, worth €867.00K. The average tenure of the management team and the board of directors is 4.6 years and 5.1 years respectively.
Key information
Jamal El-Mosleh
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5.1yrs |
| CEO ownership | 8.4% |
| Management average tenure | 4.6yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
CEO
Jamal El-Mosleh (43 yo)
5.1yrs
Tenure
Mr. Jamal El-Mosleh, M.Sc., is Co-Founder at Elicera Therapeutics AB (publ) and has been its CEO since 2020. He was a Director of Elypta AB since 2016 until September 2020. Mr. El-Mosleh served as Chief Ex...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Co-Founder | 5.1yrs | no data | 8.39% € 867.0k | |
| Chief Science Officer | 5.1yrs | no data | 9.6% € 992.0k | |
| Co-Founder & Head of Transitional Research | no data | no data | 9.76% € 1.0m | |
| Chief Financial Officer | 4.1yrs | no data | no data | |
| Head of Regulatory Affairs | 2.1yrs | no data | no data |
4.6yrs
Average Tenure
51.5yo
Average Age
Experienced Management: 8E8's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Science Officer | 11.1yrs | no data | 9.6% € 992.0k | |
| Independent Director | 5.1yrs | no data | no data | |
| Independent Chairman | 5.1yrs | no data | no data | |
| Independent Director | 5.1yrs | no data | no data | |
| Independent Director | 1.1yrs | no data | no data |
5.1yrs
Average Tenure
63yo
Average Age
Experienced Board: 8E8's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 11:13 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elicera Therapeutics AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fredrik Thor | Redeye |